Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or EASD e Learning Provided by leading diabetes academics Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet